Skip to main content
PEPTARA LABS
Get Started

MK-677 Research

MK-677 Research: What the Older-Adult Trial Tested

Published by · Updated · How we research and check our pages

The short answer

MK-677 research rests mainly on one human trial: a randomized, placebo-controlled study of 65 healthy older adults who took MK-677 by mouth (Nass et al., Ann Intern Med 2008). Over 12 months, the MK-677 group showed higher growth hormone and IGF-1, about 1.1 kg more fat-free mass than placebo, and also higher fasting blood glucose with lower insulin sensitivity (Nass et al., 2008). We do not print the amount those volunteers took. It was chosen for older adults who were checked by a study team, Peptara Labs supplies MK-677 to laboratories as a research compound, and whether a person should use it at all is a call for a qualified clinician. MK-677 (ibutamoren) is an orally active ghrelin mimetic and is not an approved medicine.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What is MK-677 and how does it work?

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that signals the pituitary gland to release more growth hormone, which then raises IGF-1 (Nass et al., 2008).

Because it mimics ghrelin, MK-677 is grouped with the growth hormone secretagogues, a class of compounds that prompt the body's own growth hormone release rather than adding growth hormone directly. What sets MK-677 apart from most of the class is the route: it is active by mouth, so the trial gave it by mouth rather than by injection (Nass et al., 2008). Injectable secretagogues work through related but different pathways. CJC-1295 is a growth hormone releasing hormone analog that raised mean growth hormone about 2 to 10 fold and IGF-1 about 1.5 to 3 fold in healthy adults (Teichman et al., JCEM 2006), and ipamorelin is a selective growth hormone secretagogue with minimal effect on cortisol and prolactin (Raun et al., Eur J Endocrinol 1998).

What did the main MK-677 trial measure?

Published research reports one main human protocol for MK-677: an oral regimen tested in healthy older adults, with the primary analysis reported at 12 months (Nass et al., 2008).

That trial randomized 65 healthy older adults, about 60 to 81 years of age, to either MK-677 or placebo. The table below summarizes what the study measured. Every figure here is a result researchers recorded in that trial, not a suggestion for personal use.

ParameterWhat the study reportedSource
RouteOral (by mouth)Nass et al., 2008
Population65 healthy older adults, about 60 to 81 yearsNass et al., 2008
Duration12-month primary analysis (trial ran up to 2 years)Nass et al., 2008
Growth hormone and IGF-1Raised toward the range seen in healthy young adultsNass et al., 2008
Fat-free massAbout 1.1 kg higher than placebo (0.7 to 1.5 kg)Nass et al., 2008
Fasting blood glucoseRose about 0.3 mmol/LNass et al., 2008
Insulin sensitivityDeclinedNass et al., 2008

Everyone in the MK-677 group took the same fixed oral amount, so the trial shows what that one regimen did in that group. It does not show how a different amount would behave, and it is not a personal instruction (Nass et al., 2008).

What did MK-677 do to glucose and insulin in the trial?

Participants taking MK-677 showed higher fasting blood glucose, about 0.3 mmol/L, and reduced insulin sensitivity over the trial (Nass et al., 2008).

This is the finding that matters most when people copy a research dose without a clinician. Higher growth hormone can blunt insulin's effect, and in this trial the same protocol that raised IGF-1 and fat-free mass also raised fasting glucose and lowered insulin sensitivity (Nass et al., 2008). The trial reported these as measurable changes over months of use. That combination, more IGF-1 but weaker glucose control, is why the metabolic side of MK-677 belongs in a conversation with a qualified clinician, especially for anyone who already tracks blood sugar.

How does MK-677 compare with injectable secretagogues?

MK-677 was studied as an oral compound, while peptides like CJC-1295 and ipamorelin were studied as injectables (Teichman et al., 2006; Raun et al., 1998).

The MK-677 research picture is different from the injectable secretagogues mostly because of route and how the compound is measured. MK-677 is swallowed. The injectable peptides are delivered under the skin. The grid below compares the class at a high level, with a source for each row. It does not list doses for any of them, because a research dose for one compound is not transferable to another.

CompoundClassRoute studiedWhat research reportedSource
MK-677 (ibutamoren)Ghrelin mimetic, GH secretagogueOralRaised GH, IGF-1, and fat-free mass; also raised glucoseNass et al., 2008
CJC-1295GHRH analogInjectableSustained GH and IGF-1 elevationTeichman et al., 2006
IpamorelinGhrelin mimetic, GH secretagogueInjectableSelective GH releaseRaun et al., 1998

Is MK-677 approved, and what side effects did research report?

MK-677 is not approved as a medicine, and the clearest signals from the trial were higher fasting glucose, lower insulin sensitivity, and increased appetite (Nass et al., 2008).

MK-677 is sold and handled as a research compound, not a prescription product. In the trial, the glucose and insulin changes appeared over months of use, and appetite rose in a way that fits its action as a ghrelin mimetic, though that appetite increase subsided within a few months (Nass et al., 2008). The study also noted transient, mild lower-limb swelling and muscle pain (Nass et al., 2008). None of this is a medical claim about what MK-677 does for a person outside a study; it is a summary of what one controlled trial measured. Human data on MK-677 remains limited to a small number of studies, so long-term effects at any dose are not fully characterized.

Why should any personal MK-677 decision go through a clinician?

Because the studied dose raised blood glucose and lowered insulin sensitivity, and because MK-677 is not an approved medicine, any decision about personal use belongs with a qualified clinician (Nass et al., 2008).

The amount used in that trial (Nass et al., 2008) is easy to find online and easy to copy, but a research protocol in monitored healthy adults is not a plan for an individual. A clinician can weigh personal factors that a trial average cannot, including blood sugar, existing conditions, and other compounds. This page reports what the research measured as background for questions to a clinician, not as a dose for anyone.

MK-677 Research: FAQ

Which study is most cited for MK-677?

The most-cited human study is Nass et al. (2008), a randomized, placebo-controlled trial in 65 healthy older adults who took MK-677 by mouth, with results reported at 12 months. This page leaves out the amount that trial used, because a study figure is not a recommendation for anyone.

Is MK-677 taken orally or injected?

Orally. MK-677 is active by mouth, which is the main practical difference from injectable secretagogues like CJC-1295 (Teichman et al., 2006) and ipamorelin (Raun et al., 1998).

Does MK-677 affect blood sugar?

Yes. People taking MK-677 in the trial had higher fasting blood glucose, about 0.3 mmol/L, and reduced insulin sensitivity (Nass et al., 2008), which is why the metabolic side is worth reviewing with a clinician.

How long did the MK-677 study run?

The primary analysis covered 12 months of oral treatment in healthy older adults, and the full trial ran up to 2 years (Nass et al., 2008).

Did MK-677 increase muscle in the trial?

Participants gained about 1.1 kg of fat-free mass versus placebo (Nass et al., 2008). That is a trial measurement, not a promise of muscle gain for any individual.

Is MK-677 approved for human use?

No. MK-677 is handled as a research compound and is not an approved medicine, so personal decisions should route to a qualified clinician.

References

  1. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003. PMID: 18981485. PMCID: PMC2757071.
  2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
  3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID: 9849822.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us